Loading...
•
Sep 30, 2023
Marinus Pharmaceuticals Q3 2023 Earnings Report
Marinus Pharmaceuticals reported strong quarter over quarter growth with ZTALMY net product revenue of $5.4 million and increased its 2023 net product revenue guidance.
Key Takeaways
Marinus Pharmaceuticals reported its Q3 2023 financial results, highlighting a ZTALMY net product revenue of $5.4 million. The company increased its full year 2023 expected ZTALMY net product revenues to between $18.5 and $19 million. The company's cash runway is projected into Q4 2024, with cash, cash equivalents, and short-term investments of $176.4 million as of September 30, 2023.
ZTALMY net product revenue reached $5.4 million in Q3 2023.
Full year 2023 ZTALMY net product revenue guidance increased to between $18.5 and $19 million.
Over 75% of patients required for the interim analysis are now enrolled in the Phase 3 RAISE trial in refractory status epilepticus.
Cash runway projected into Q4 2024 with $176.4 million in cash, cash equivalents, and short-term investments as of September 30, 2023.
Revenue by Segment
Forward Guidance
Marinus Pharmaceuticals updated its revenue and operating expense guidance for the fiscal year 2023.
Positive Outlook
- The Company now expects ZTALMY net product revenues of between $18.5 and $19 million; this represents an increase from the previous guidance of between $17 and $18.5 million
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...